(!8 mg/mL), amikacin (!16 mg/mL), and trimethoprim-sulfamethoxazole (!2/38 mg/mL). It was resistant to ampicillin (116 mg/mL), piperacillin (116 mg/mL), ticarcillin/clavulanate (164 mg/mL), cefazolin (116 mg/mL), and imipenem (18 mg/mL), and it showed intermediate resistance to gentamicin (8 mg/mL) and tobramycin (8 mg/mL).
There have been at least 19 reports of human infection caused by CDC IV c-2 [1, 4] . Many of these are included in the recent review by Thayu et al. [1] . These include 16 patients with septicemia, 2 with peritonitis complicating peritoneal dialysis, and 1 with tenosynovitis. All infections, except that in a 73-yearold with cat bite-associated tenosynovitis, occurred in patients with underlying diseases, especially immunosuppression. Eleven infections were considered nosocomial, but 6 additional patients required frequent medical intervention. Fourteen patients had permanent venous catheters, and 2 had peritoneal catheters for dialysis.
Our patient is, to our knowledge, the first apparently immunocompetent host with bacteremia caused by CDC group IV c-2. Her appropriate growth and development and lack of prior infections, together with the normal laboratory findings, suggest that her immune system was intact. Her presentation was consistent with an occult bacteremia that either was selflimited or responded to antimicrobial therapy. The possibility remains that she had a subtle defect in immune function that was not elucidated. The susceptibility of this isolate to aminoglycosides is unusual but has been reported elsewhere [5] .
In summary, CDC group IV c-2 is an infrequent cause of human infection; most such infections occur in hospitalized, immunosuppressed patients. Our patient's presentation illustrates that invasive infection can occasionally occur in immunocompetent hosts.
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